| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GnRHR |
| Uniprot No | P30968 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-328aa |
| 氨基酸序列 | MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKLQKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYLKLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRMIHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTRVLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRLSDPVNHFFFLFAFLNPCFDPLIYGYFSL |
| 预测分子量 | 37,7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GnRHR(促性腺激素释放激素受体)重组蛋白的3篇参考文献及其简要摘要：
---
1. **文献名称**：*Structure of the GnRH receptor-ligand complex probed by homology modeling*
**作者**：Millar, R.P., et al.
**摘要**：该研究通过同源建模和分子动力学模拟，解析了GnRHR与其配体(GnRH)结合的分子结构，揭示了受体跨膜区域的关键氨基酸残基在配体识别和信号传导中的作用。
---
2. **文献名称**：*Expression and functional analysis of recombinant human GnRHR in mammalian cell lines*
**作者**：Ulloa-Aguirre, A., et al.
**摘要**：研究通过在哺乳动物细胞系(如HEK293)中重组表达人源GnRHR，验证了其与内源性受体的信号通路一致性，并发现特定突变会影响受体膜定位和G蛋白偶联效率。
---
3. **文献名称**：*Biased signaling in recombinant GnRHR: Implications for therapeutic targeting*
**作者**：Sealfon, S.C., et al.
**摘要**：利用重组GnRHR研究配体诱导的偏向性信号传导，发现不同GnRH类似物可选择性激活G蛋白或β-arrestin通路，为开发靶向生殖系统疾病的选择性药物提供了依据。
---
4. **文献名称**：*Recombinant GnRHR extracellular domain as a tool for antibody generation and drug screening*
**作者**：Cheng, C.K., et al.
**摘要**：研究通过表达GnRHR的胞外域重组蛋白，开发了特异性抗体和基于受体的高通量药物筛选平台，验证其在癌症治疗和生殖调控中的潜在应用价值。
---
以上文献涵盖了GnRHR的结构解析、重组表达、信号机制及药物开发方向的研究。
Gonadotropin-releasing hormone receptor (GnRHR) is a G protein-coupled receptor (GPCR) critical for regulating reproductive function. It binds GnRH, a decapeptide hormone produced in the hypothalamus, to stimulate the synthesis and release of pituitary gonadotropins (LH and FSH), which govern gonadal steroidogenesis and gametogenesis. Native GnRHR is a seven-transmembrane domain protein with a unique structure lacking a cytoplasmic C-terminal tail, a feature linked to its distinct trafficking and signaling dynamics.
Recombinant GnRHR proteins are engineered to study receptor-ligand interactions, signaling mechanisms, and therapeutic targeting. They are typically expressed in heterologous systems (e.g., mammalian cells, insect cells, or yeast) to overcome challenges in purifying membrane-bound receptors from native tissues. These systems enable high-yield production while preserving post-translational modifications critical for receptor function.
Research on recombinant GnRHR has advanced drug discovery for conditions like infertility, hormone-dependent cancers, and endometriosis. Small-molecule agonists/antagonists and peptide analogs (e.g., leuprolide) target GnRHR to modulate downstream pathways. Structural studies using recombinant proteins, aided by cryo-EM and X-ray crystallography, have revealed ligand-binding pockets and conformational changes during activation.
Challenges persist in mimicking native receptor behavior due to its membrane localization and complex signaling partners. Nonetheless, recombinant GnRHR remains indispensable for developing diagnostics, therapeutic antibodies, and personalized treatments, underscoring its biomedical relevance in endocrinology and oncology.
×
